Germany's booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory. As the landmark CanG Act approaches its second year, it has become a highly charged and increasingly divisive issue politically, culturally, and medically.
With the recent ousting of the Traffic Light Coalition, responsible for creating and pushing through partial cannabis legalisation, the new Christian Democrat (CDU) led coalition has ramped up its anti-cannabis rhetoric and has consistently and publicly threatened to restrict or even roll back the changes brought about over the last 18 months.
The first interim report on the impact of the reforms has now been published, marking the first in a string of upcoming events which could define the future of the industry.
The findings of the 'Ekocan' report have already caused a stir among commentators on both sides of the aisle, with some suggesting it points to a wholesale failure to meet its intended goal of protecting consumers and reducing the illicit market, and others suggesting it shows positive progress at such an early stage.
Read more at Cannabis Health
